How HERCULES helpspharma companies
Developing a treatment for Duchenne muscular dystrophy is a huge achievement.
But getting that treatment to patients depends on more than science—it depends on health technology assessment (HTA).
For pharmaceutical companies, this process can be complex, especially for rare conditions. That’s where our work helps.
The challenge
HTA decisions rely on strong evidence about cost-effectiveness and patient benefit.
For rare diseases, the data is often limited, which can lead to delays or negative decisions.
This creates uncertainty for companies and, most importantly, for families waiting for treatment.
Our solution
When HTA decisions are based on robust, patient-centred evidence, treatments reach the market faster. That benefits families—and it benefits companies by reducing risk and uncertainty. Together, we can make sure innovation translates into access.
Through HERCULES, we’ve built a collaborative framework that brings together patient organisations, industry, and experts to create better evidence for DMD.
What we provide:
Research and Care
Shared tools and models for economic evaluation
Trusted information
Patient-reported data on quality of life and disease progression
Help in Emergencies
Insights from real-world experience to strengthen submissions
In summary
HERCULES provides evidence that makes HTA submissions stronger and more consistent. This reduces duplication, saves time, and improves the chances of a positive outcome.
